MyChesCo on MSN18h
INOVIO’s INO-3107 Shows Powerful Potential for Treating Recurrent Respiratory Papillomatosis
INOVIO (NASDAQ: INO) has unveiled promising peer-reviewed results from its Phase 1/2 clinical trial for INO-3107, a ...
INO-3107 shows promise in reducing surgeries for RRP patients
PLYMOUTH MEETING, Pa. - INOVIO (NASDAQ: INO), a biotechnology company with a market capitalization of approximately $69 million, has announced positive results from a Phase 1/2 clinical trial of ...
Inovio announces peer-reviewed data from phase 1/2 clinical trial with INO-307
Inovio (INO) announced that peer-reviewed data from its Phase 1/2 clinical trial with INO-3107 as a potential treatment for recurrent ...
standard-journal2d
Kraft Heinz: Q4 Earnings Snapshot
PITTSBURGH (AP) — PITTSBURGH (AP) — The Kraft Heinz Company (KHC) on Wednesday reported fourth-quarter earnings of $2.13 billion. On a per-share basis, the Pittsburgh-based company said it had net ...
Precigen: Successful Proof Of Platform, But Cash Worries Remain
Precigen has a market cap of $468mn and a cash runway into 2026, but needs more funds for commercialization. Check out my ...
Medindia5d
Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference
Poster will describe loss of detectable HPV-6 in Recurrent Respiratory Papillomatosis patients following treatment with INO-3107 American Association for Cancer Research – Immuno-Oncology Discovery ...